A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
Phase 2
Not yet recruiting
- Conditions
- Hepatocellular Cancer
- Interventions
- Drug: SHR-1826 and immunotherapy combination therapy
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 53
- Registration Number
- NCT06935175
- Locations
- 🇨🇳
Shanghai Zhongshan Hospital, Shanghai, China
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Phase 1
Recruiting
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT06754930
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-11-25
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 876
- Registration Number
- NCT06703177
- Locations
- 🇨🇳
Sun Yat-Sen university cancer center, Guangzhou, Guangdong, China
An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06094556
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath